- Home
- BEATW vs CPRT Comparison
BEATW vs CPRT Comparison
Compare BEATW & CPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- CPRT
- Stock Information
- Founded
- BEATW 2015
- CPRT 1982
- Country
- BEATW United States
- CPRT United States
- Employees
- BEATW 21
- CPRT N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- CPRT Other Specialty Stores
- Sector
- BEATW Technology
- CPRT Consumer Discretionary
- Exchange
- BEATW Nasdaq
- CPRT Nasdaq
- Market Cap
- BEATW N/A
- CPRT N/A
- IPO Year
- BEATW N/A
- CPRT 1994
- Fundamental
- Price
- BEATW $0.60
- CPRT $60.90
- Analyst Decision
- BEATW
- CPRT Buy
- Analyst Count
- BEATW 0
- CPRT 2
- Target Price
- BEATW N/A
- CPRT $58.00
- AVG Volume (30 Days)
- BEATW 4.7K
- CPRT 5.9M
- Earning Date
- BEATW 03-14-2025
- CPRT 05-15-2025
- Dividend Yield
- BEATW N/A
- CPRT N/A
- EPS Growth
- BEATW N/A
- CPRT 6.46
- EPS
- BEATW N/A
- CPRT 1.49
- Revenue
- BEATW N/A
- CPRT $4,506,403,000.00
- Revenue This Year
- BEATW N/A
- CPRT $13.53
- Revenue Next Year
- BEATW N/A
- CPRT $9.23
- P/E Ratio
- BEATW N/A
- CPRT $40.87
- Revenue Growth
- BEATW N/A
- CPRT 11.00
- 52 Week Low
- BEATW $0.50
- CPRT $48.05
- 52 Week High
- BEATW $0.62
- CPRT $64.38
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- CPRT 62.41
- Support Level
- BEATW N/A
- CPRT $60.24
- Resistance Level
- BEATW N/A
- CPRT $62.09
- Average True Range (ATR)
- BEATW 0.00
- CPRT 2.00
- MACD
- BEATW 0.00
- CPRT 0.31
- Stochastic Oscillator
- BEATW 0.00
- CPRT 88.52
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.